How Cosentyx Improves Skin Conditions
Cosentyx (secukinumab) targets interleukin-17A (IL-17A), a protein driving inflammation in autoimmune skin diseases. By blocking IL-17A, it reduces plaque buildup, redness, scaling, and itching. In psoriasis trials, 80-90% of moderate-to-severe plaque psoriasis patients achieved at least 75% skin clearance (PASI 75) after 12 weeks, with many reaching near-complete clearance (PASI 90 or 100).[1][2]
Effects on Psoriasis
Cosentyx clears psoriatic plaques faster than some older biologics. Patients often see major improvements within 4 weeks, with sustained results over years in long-term studies. It also reduces scalp and nail psoriasis, areas resistant to topicals.[1]
Benefits for Hidradenitis Suppurativa
For moderate-to-severe hidradenitis suppurativa (HS), Cosentyx lessens painful nodules, abscesses, and tunnels by curbing IL-17-driven inflammation. Phase 3 trials showed 45-50% of patients had fewer lesions (HiSCR response) at week 16, versus 30-35% on placebo.[3]
Impact on Other Skin Issues
- Psoriatic Arthritis-Related Skin Symptoms: Clears psoriasis in 70-80% of patients while easing joint pain.[1]
- No Direct Role in Acne or Eczema: It does not treat these, as they involve different pathways (e.g., IL-4/13 in eczema).[2]
Common Skin Side Effects
Injection-site reactions occur in 10-15% of users, typically mild redness or itching that fades quickly. Fungal skin infections (e.g., candida) rise slightly due to IL-17's role in antifungal defense, affecting 2-4%.[1][4] Rare severe reactions include exfoliative dermatitis.
What Happens with Long-Term Use
Skin improvements hold for 5+ years in extensions, but 5-10% develop anti-drug antibodies, potentially reducing efficacy. Monitoring for new infections is standard.[1]
Who Should Avoid It
Patients with active infections or tuberculosis risk face higher skin infection odds. It's not for mild cases topicals handle.[4]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Approval Summary for Psoriasis
[3]: Phase 3 SUNRISE Trial (NEJM, 2023)
[4]: Drugs.com Cosentyx Side Effects